Spots Global Cancer Trial Database for mek inhibitor
Every month we try and update this database with for mek inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants | NCT03649165 | Neurofibromatos... Healthy Partici... | Treatment A Treatment B Treatment C Treatment D Acetaminophen | 18 Years - 45 Years | AstraZeneca | |
| MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma | NCT04216953 | Sarcoma,Soft Ti... | Cobimetinib Atezolizumab | 12 Years - | Centre Leon Berard | |
| Association of Hydroxychloroquine, BRAF and MEK Inhibitors in Metastatic Melanoma : a Retrospective Case-control Study. | NCT04760080 | Dermatology and... | pre-treatment d... during study tr... | 18 Years - | Hospices Civils de Lyon | |
| Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma | NCT00687622 | Solid Tumours | GSK1120212 | 18 Years - | GlaxoSmithKline | |
| Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors | NCT00996892 | Solid Tumors | Cobimetinib Pictilisib | 18 Years - | Genentech, Inc. | |
| Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer. | NCT01204177 | Carcinoma, Hepa... | BAY86-9766 MEK ... | 18 Years - | Bayer | |
| Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel | NCT01192165 | Cancer | Trametinib (GSK... Docetaxel Erlotinib Pemetrexed Carboplatin nab-Paclitaxel Cisplatin | 18 Years - | GlaxoSmithKline | |
| A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib | NCT02382549 | Melanoma | BRAF inhibitor 6MHP MEK inhibitor | 18 Years - | University of Virginia | |
| Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors | NCT01428427 | Leukaemia, Myel... | GSK1120212 Gemcitabine | 18 Years - | GlaxoSmithKline | |
| Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases | NCT03430947 | Malignant Melan... BRAF V600 Mutat... Brain Metastase... | Vemurafenib Cobimetinib | 18 Years - | Technische Universität Dresden | |
| Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer. | NCT01204177 | Carcinoma, Hepa... | BAY86-9766 MEK ... | 18 Years - | Bayer | |
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors | NCT01938443 | Cancer Neoplasms | GSK2256098 Trametinib | 18 Years - | GlaxoSmithKline | |
| A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib | NCT02382549 | Melanoma | BRAF inhibitor 6MHP MEK inhibitor | 18 Years - | University of Virginia | |
| Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas | NCT04924608 | Neurofibromatos... Plexiform Neuro... | Selumetinib Placebo | 18 Years - | AstraZeneca | |
| Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer | NCT01938456 | Lung Cancer, No... | Trametinib Docetaxel Filgrastim | 20 Years - | GlaxoSmithKline | |
| A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors | NCT01938443 | Cancer Neoplasms | GSK2256098 Trametinib | 18 Years - | GlaxoSmithKline | |
| Trial of MSC1936369B in Subjects With Solid Tumors | NCT00982865 | Solid Tumors Cancer | MSC1936369B MSC1936369B MSC1936369B MSC1936369B | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies | NCT01725100 | Cancer | GSK1120212B (St... GSK1120212B (Lo... | 18 Years - | GlaxoSmithKline | |
| MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma | NCT03979651 | Metastatic NRAS... | Trametinib plus... Trametinib plus... Trametinib plus... | 18 Years - | Hospices Civils de Lyon | |
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma | NCT00687622 | Solid Tumours | GSK1120212 | 18 Years - | GlaxoSmithKline | |
| A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors | NCT01562275 | Neoplasms | Ipatasertib Cobimetinib | 18 Years - | Genentech, Inc. | |
| Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial | NCT01160926 | Rectal Cancer | AZD6244 Cediranib (AZD2... | 18 Years - | The Christie NHS Foundation Trust | |
| Trial of Pimasertib in Hematological Malignancies | NCT00957580 | Leukemia, Myelo... Hematologic Neo... | Pimasertib Pimasertib Pimasertib Pimasertib Pimasertib | 18 Years - | EMD Serono | |
| MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma | NCT04216953 | Sarcoma,Soft Ti... | Cobimetinib Atezolizumab | 12 Years - | Centre Leon Berard | |
| Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212 | NCT01387204 | Cancer | GSK1120212 | 18 Years - | GlaxoSmithKline | |
| BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) | NCT01750918 | Cancer | Dabrafenib Trametinib Panitumumab 5-fluorouracil | 18 Years - | Novartis | |
| Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). | NCT01682083 | Melanoma | Dabrafenib Trametinib Placebos | 18 Years - | Novartis | |
| MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC) | NCT01085331 | Metastatic Colo... | Pimasertib Placebo FOLFIRI | 18 Years - | EMD Serono | |
| MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas | NCT03962543 | Plexiform Neuro... Neurofibromatos... | Mirdametinib (P... | 2 Years - | SpringWorks Therapeutics, Inc. | |
| A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers | NCT01943864 | Cancer | Trametinib (sin... Trametinib (Mul... | 20 Years - 80 Years | GlaxoSmithKline | |
| Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer | NCT01016483 | Pancreatic Aden... | Pimasertib Gemcitabine Placebo | 18 Years - | EMD Serono | |
| Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 | NCT01072175 | Cancer | GSK2118436 GSK1120212 | 18 Years - | Novartis | |
| GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma | NCT01245062 | Melanoma | GSK1120212 Chemotherapy | 18 Years - | GlaxoSmithKline | |
| Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus | NCT01378377 | Advanced Solid ... | Pimasertib Pimasertib Temsirolimus Temsirolimus | 18 Years - | EMD Serono | |
| Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma | NCT00687622 | Solid Tumours | GSK1120212 | 18 Years - | GlaxoSmithKline | |
| A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors | NCT01562275 | Neoplasms | Ipatasertib Cobimetinib | 18 Years - | Genentech, Inc. | |
| Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases | NCT03430947 | Malignant Melan... BRAF V600 Mutat... Brain Metastase... | Vemurafenib Cobimetinib | 18 Years - | Technische Universität Dresden | |
| A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients | NCT01155453 | Advanced and Se... | BKM120 GSK1120212 | 18 Years - | Novartis | |
| Intermittent Selumetinib for Uveal Melanoma | NCT02768766 | Uveal Melanoma | Selumetinib, 10... Selumetinib, 12... Selumetinib, 15... Selumetinib, 17... Selumetinib, 20... Selumetinib, 22... | 18 Years - | Columbia University | |
| Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212 | NCT01387204 | Cancer | GSK1120212 | 18 Years - | GlaxoSmithKline | |
| MEK Inhibitor and Thoracic Radiotherapy Trial | NCT01146756 | Non Small Cell ... | AZD6244 | 18 Years - | The Christie NHS Foundation Trust | |
| Trial of Pimasertib in Hematological Malignancies | NCT00957580 | Leukemia, Myelo... Hematologic Neo... | Pimasertib Pimasertib Pimasertib Pimasertib Pimasertib | 18 Years - | EMD Serono | |
| Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors | NCT00996892 | Solid Tumors | Cobimetinib Pictilisib | 18 Years - | Genentech, Inc. | |
| Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212 | NCT01387204 | Cancer | GSK1120212 | 18 Years - | GlaxoSmithKline | |
| Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors | NCT01324258 | Solid Tumours | GSK1120212 Gemcitabine | 20 Years - | GlaxoSmithKline | |
| Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). | NCT01682083 | Melanoma | Dabrafenib Trametinib Placebos | 18 Years - | Novartis | |
| A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers | NCT01476137 | Cancer | GSK1120212 GSK2110183 | 18 Years - | GlaxoSmithKline | |
| Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors | NCT01324258 | Solid Tumours | GSK1120212 Gemcitabine | 20 Years - | GlaxoSmithKline | |
| Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor | NCT01037127 | Cancer | GSK1120212 | 18 Years - | GlaxoSmithKline | |
| MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas | NCT03962543 | Plexiform Neuro... Neurofibromatos... | Mirdametinib (P... | 2 Years - | SpringWorks Therapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
